MB-107

N/A

Report date: 2023/10/26 16:20:56

Base Information

Drug NameMB-107
Drug Alias NameVSV-G pseudotyped CL20-4i-EF1α-hγc-OPTGene-modified CD34+ hematopoietic stem cellsCL20-4i-EF1alpha- HgammaC-OPTMB-107 XSCID gene therapyCL20-i4-EF1α-hγc-OPT +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy +[4] 
Mechanisms of ActionIL-2RG gene transference
TargetsInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsImmunologic Deficiency SyndromesX-Linked Combined Immunodeficiency Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSt. Jude Children'S Research HospitalNational Institute Of Allergy And Infectious Diseases (Niaid)National Heart, Lung And Blood Institute +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthNational Heart, Lung And Blood InstituteMustang Bio Inc +[5] 
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency Syndromes
Inactive IndicationsX-Linked Combined Immunodeficiency Diseases

Other Information

ATC CodeN/A
Related LinksN/A